These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9003064)

  • 1. Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals.
    Santiago M; Matarredona ER; Granero L; Cano J; Machado A
    J Neurochem; 1997 Feb; 68(2):732-8. PubMed ID: 9003064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine.
    Matarredona ER; Santiago M; Cano J; Machado A
    Brain Res; 1997 Oct; 773(1-2):76-81. PubMed ID: 9409707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate.
    Matarredona ER; Santiago M; Machado A; Cano J
    Br J Pharmacol; 1997 Jul; 121(5):1038-44. PubMed ID: 9222565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nigral and striatal comparative study of the neurotoxic action of 1-methyl-4-phenylpyridinium ion: involvement of dopamine uptake system.
    Santiago M; Machado A; Cano J
    J Neurochem; 1996 Mar; 66(3):1182-90. PubMed ID: 8769882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of desferrioxamine, a strong iron (III) chelator, on 1-methyl-4-phenylpyridinium ion (MPP+)-induced hydroxyl radical generation in the rat striatum.
    Obata T
    Eur J Pharmacol; 2006 Jun; 539(1-2):34-8. PubMed ID: 16650845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals.
    Santiago M; Matarredona ER; Granero L; Cano J; Machado A
    Brain Res; 2000 Mar; 858(1):26-32. PubMed ID: 10700592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effect of apomorphine and haloperidol on MPP neurotoxicity.
    Espinosa-Oliva AM; de Pablos RM; Santiago M
    Pharmacology; 2014; 93(3-4):101-7. PubMed ID: 24556705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo protection of striatal dopaminergic system against 1-methyl-4-phenylpyridinium neurotoxicity by phenobarbital.
    Vizuete ML; Merino M; Cano J; Machado A
    J Neurosci Res; 1997 Aug; 49(3):301-8. PubMed ID: 9260741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased extracellular glutamate evoked by 1-methyl-4-phenylpyridinium [MPP(+)] in the rat striatum is not essential for dopaminergic neurotoxicity and is not derived from released glutathione.
    Foster SB; Tang H; Miller KE; Dryhurst G
    Neurotox Res; 2005; 7(4):251-63. PubMed ID: 16179262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.
    Merino M; Vizuete ML; Cano J; Machado A
    J Neurochem; 1999 Aug; 73(2):750-7. PubMed ID: 10428073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal ablation of GABAergic neurons prevents the in vivo neuroprotective effect of DCG-IV against the MPP+-induced neurotoxicity on dopaminergic nerve terminals.
    Venero JL; Mauriño R; Machado A; Santiago M
    Neurochem Int; 2010 Dec; 57(8):979-84. PubMed ID: 20974202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis.
    Santiago M; Machado A; Cano J
    J Neurosci Methods; 2001 Jul; 108(2):181-7. PubMed ID: 11478977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP+ does not.
    Santiago M; Hernández-Romero MC; Machado A; Cano J
    Eur J Pharmacol; 2009 May; 609(1-3):58-64. PubMed ID: 19292984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.
    Espino A; Cutillas B; Tortosa A; Ferrer I; Bartrons R; Ambrosio S
    Brain Res; 1995 Oct; 695(2):151-7. PubMed ID: 8556325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction.
    Matarredona ER; Santiago M; Venero JL; Cano J; Machado A
    J Neurochem; 2001 Jan; 76(2):351-60. PubMed ID: 11208898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of dopamine by perfusion with 1-methyl-4-phenylpyridinium ion (MPP(+)) into the striatum is associated with hydroxyl free radical generation.
    Obata T; Yamanaka Y; Kinemuchi H; Oreland L
    Brain Res; 2001 Jul; 906(1-2):170-5. PubMed ID: 11430875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study.
    Di Matteo V; Benigno A; Pierucci M; Giuliano DA; Crescimanno G; Esposito E; Di Giovanni G
    Ann N Y Acad Sci; 2006 Nov; 1089():462-71. PubMed ID: 17261789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of L-arginine/nitric oxide pathway on MPP(+)-induced cell injury in the striatum of rats.
    Santiago M; Machado A; Cano J
    Br J Pharmacol; 1994 Mar; 111(3):837-42. PubMed ID: 8019760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Vaglini F; Pardini C; Cavalletti M; Maggio R; Corsini GU
    Brain Res; 1996 Nov; 741(1-2):68-74. PubMed ID: 9001706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo protection of striatum from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists.
    Santiago M; Venero JL; Machado A; Cano J
    Brain Res; 1992 Jul; 586(2):203-7. PubMed ID: 1521154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.